Secukinumab for heart and kidney health in metabolic disease
Treatments studied
Part of Brain & nervous system, Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if secukinumab, a medicine for inflammation, can improve heart and kidney outcomes in people with cardiorenal metabolic syndrome and atherosclerotic cardiovascular disease. It may help if you have conditions like obesity, diabetes, high blood pressure, kidney issues, and hardened arteries.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have at least one metabolic condition, such as excess weight, high waist size, prediabetes or diabetes, high triglycerides, high blood pressure, or metabolic syndrome.
- You have chronic kidney disease, like moderately to severely reduced kidney function or high protein in urine with normal kidney function.
- You have documented hardening of the arteries in the heart, brain, or legs (e.g., past heart attack, stroke, or blocked arteries).
- You do not have active infections, recent heart attack or stroke within 2 months, or use of immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called clazakizumab to see if it can reduce the risk of heart attacks, strokes, or cardiovascular death in people with high inflammation and certain chronic conditions like heart disease, diabetes, or kidney disease. Participation may help researchers learn if this treatment is safe and effective for this population.
This study looks at how secukinumab affects heart health in people with moderate-to-severe hidradenitis suppurativa (HS) who also have high cardiovascular risk or existing plaque in their heart arteries. It aims to see if this treatment might help both their skin and heart.
This trial tests a medication called secukinumab for people with active, severe Takayasu arteritis, a disease that causes inflammation in large blood vessels. The goal is to see if secukinumab can help control the disease better than standard treatments alone.
This trial studies whether secukinumab (a targeted medicine given by injection) can reduce symptoms and disease activity in adults with active ankylosing spondylitis. You may be considered if other common anti-inflammatory medicines have not worked well enough or you could not take them.
This study looks at how well secukinumab works for psoriasis patients who also have a type of fatty liver disease called MASLD. It may help doctors understand if this treatment is a good option for people with both conditions.
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
Hear when a new Atherosclerotic Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.